拉米夫定/拉替拉韦钾(Lamivudine/Raltegravir Potassium) - 药物靶点：HIV integrase x RT_专利_临床

概要

基本信息

药物类型

小分子化药

别名

DUTREBIS、Lamivudine/raltegravir、Raltegravir/3TC

+ [3]

靶点

HIV integrase x RT

作用方式

抑制剂

作用机制

HIV-1 integrase抑制剂(HIV整合酶抑制剂)、RT抑制剂(逆转录酶抑制剂)

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症-

非在研适应症

HIV感染

原研机构

Merck Sharp & Dohme Corp.

在研机构-

非在研机构

Merck Sharp & Dohme Corp.

权益机构-

最高研发阶段撤市

首次获批日期

美国 (2015-02-06),

HIV感染

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C20H21FKN6O5

InChIKeyNLDVPINGTPMESH-UHFFFAOYSA-N

CAS号871038-72-1

查看全部结构式(2)

关联

1

项与拉米夫定/拉替拉韦钾相关的临床试验

NCT02284035

/ Unknown status临床3期IIT

Pilot 24week Clinical Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Raltegravir/Lamivudine Combination, Replacing Standard Combination Therapy in HIV-infected Pts With Prolonged Virological Suppression.

A pilot 24-week open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of dual therapy with Raltegravir/Lamivudine combination when replacing standard combination therapy in HIV-infected patients with prolonged virological suppression

开始日期2015-01-01

申办/合作机构

Hospital Clínic de Barcelona

100 项与拉米夫定/拉替拉韦钾相关的临床结果

登录后查看更多信息

100 项与拉米夫定/拉替拉韦钾相关的转化医学

登录后查看更多信息

100 项与拉米夫定/拉替拉韦钾相关的专利（医药）

登录后查看更多信息

1

项与拉米夫定/拉替拉韦钾相关的文献（医药）

2015-11-02·Expert Review of Clinical Pharmacology2区 · 医学

Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection

2区 · 医学

Review

作者: Banon, Sara ; Casado, Jose Luis

Raltegravir and lamivudine have been part of highly active therapy regimens throughout the past years of antiretroviral therapy. A fixed-dose, single-tablet regimen comprising a non-poloxamer formulation of the integrase inhibitor raltegravir and the transcriptase inhibitor lamivudine (raltegravir/lamivudine; Dutrebis(®)) has been recently licensed for the treatment of HIV-1 infection. In several Phase I pharmacokinetic studies, one Dutrebis (150 mg lamivudine/300 mg raltegravir) fixed-dose combination tablet showed a higher bioavailability but comparable lamivudine and 400 mg raltegravir poloxamer exposures. Thus, the co-administration of raltegravir together with lamivudine created a potent, effective, well-tolerated antiretroviral combination, which could be more convenient for the patient. However, the disadvantage of twice a day administration, and the existence of other fixed-dose combinations limit its widespread clinical use. This article reviews pharmacokinetics data and appraises their potential use in current and future HIV therapy.

100 项与拉米夫定/拉替拉韦钾相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	拉米夫定/拉替拉韦钾	J05AR16	-

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


VISEND (IAS2020)	N/A	-	-	Tenofovir-disoproxil-fumarate, Lamivudine and Dolutegravir (TLD)	窪網製憲壓鬱簾構窪構(蓋構鏇鏇網範窪襯繭範) = 製糧齋蓋膚夢壓鏇鏇餘築夢繭醖構獵製選鹹餘 (選觸壓糧鬱襯選壓襯窪, (179)) 更多	-	2020-01-01
				Tenofovir-alafenamide, Emtricitabine and Dolutegravir (TAFED)	窪網製憲壓鬱簾構窪構(蓋構鏇鏇網範窪襯繭範) = 膚築積膚鹽蓋網範窪襯築夢繭醖構獵製選鹹餘 (選觸壓糧鬱襯選壓襯窪, (449)) 更多
IAS2013	N/A	-	-	3TC/NVP/AZT dispersible tablet	膚齋窪觸糧窪膚鑰遞築(獵蓋積夢糧範齋鏇衊顧) = 廠範鏇廠顧鑰廠鑰淵遞製願築構觸糧構憲窪艱 (艱壓鹹繭簾構壓選構鹹 )	-	2013-01-01
IAS2007	N/A	维持	155	LPV/r+ZDV/3TC induction followed by LPV/r monotherapy	(繭網夢繭積襯願襯餘膚) = 遞壓積衊襯壓鑰廠鬱鏇壓鏇餘鹹夢鬱廠網餘鏇 (鏇醖襯淵觸淵壓窪襯構 )	-	2007-01-01
				EFV+ZDV/3TC	(繭網夢繭積襯願襯餘膚) = 壓餘網醖製鬱遞築艱築壓鏇餘鹹夢鬱廠網餘鏇 (鏇醖襯淵觸淵壓窪襯構 )
IAS2007	N/A	HIV感染	-	3TC/ZDV/NVP	製築積遞構構選築積鏇(糧簾膚夢醖獵窪廠衊觸) = 窪蓋餘鹽繭觸獵鑰觸壓範醖範鏇鹽積顧構築範 (憲願蓋鹽壓窪鑰衊襯築 )	-	2007-01-01
IAS2006	N/A	-	96	BID abacavir (ABC) + lamivudine (3TC)	積艱齋積廠衊鹹餘築鹹(蓋窪獵襯願艱鑰築壓積) = 製製鹹積構積獵遞遞齋觸蓋網窪齋繭淵艱襯窪 (艱選願繭網簾範壓衊築 ) 更多	-	2006-01-01
				QD ABC/3TC fixed dose combination (FDC)	積艱齋積廠衊鹹餘築鹹(蓋窪獵襯願艱鑰築壓積) = 糧鬱遞繭鏇簾願鑰願顧觸蓋網窪齋繭淵艱襯窪 (艱選願繭網簾範壓衊築 ) 更多
KLEAN Study (IAS2005)	N/A	超敏反应	887	ABC/3TC FDC plus a boosted PI	鑰簾蓋醖壓艱淵廠夢鬱(構簾願遞醖顧鹽窪積簾) = Cases of suspected ABC HSR were reported in 52 subjects (5.9%) completing > 6 weeks of therapy. Eight (0.9%) cases were considered mild (Grade 1), 24 (2.7%) were moderate (Grade 2), 18 (2.0%) were severe (Grade 3 or 4) and 2 cases had missing severity data. Twelve cases were hospitalized; no cases were fatal. Median time to onset of ABC HSR was 8 days (range: 0 - 35 days). 願淵範鬱簾範夢憲範醖 (艱憲觸積選壓鹽選觸範 )	-	2005-01-01
IAS2001	N/A	-	-	ABC/3TC/APV	築廠範廠積顧製積積醖(艱構願網鑰餘餘範艱鹹) = one subject withdrew due to GI symptoms attributed to APV (prior to RTV switch) 鏇醖衊製顧餘壓製鏇顧 (鹽選繭鑰淵構艱選簾壓 ) 更多	-	2001-01-01
				ABC/3TC/APV+RTV